Abstract 1044P
Background
Currently, there is limited research focusing on the treatments for HER2-altered advanced non-small cell lung cancer (NSCLC) progressed beyond first-line treatments, especially on evaluating the benefit of taxanes in the second or third-line setting. The retrospective real-world study aimed to assess the efficacy of various kinds of taxanes, including nab-paclitaxel, paclitaxel, and docetaxel on such patients. The research further compared the efficacy of taxanes-based chemotherapy alone (C), and combined with angiogenesis inhibitors (C+A) or immune checkpoint inhibitors (C+I) for HER2-altered NSCLC.
Methods
HER2-altered NSCLC patients who received taxanes-based treatment as the second or third-line setting between November 2015 and September 2021 were screened. Patients treated with different kinds of taxanes and various strategies including C, C+I, or C+A were included for final efficacy analysis. Progression-free survival (PFS) were compared between subgroups.
Results
A total of 52 patients were finally included. C+I achieved longer PFS than C (median, 5.70 vs.4.27 months, hazard ratio 0.39, 95% CI: 0.16-0.92, p=0.003). A clinically meaningful improvement in PFS was observed among patients in the nab-paclitaxel group compared with those in the docetaxel group (median, 6.40 vs. 4.03 months, hazard ratio 0.34, 95%CI: 0.16-0.71, p=0.003). There was no difference between C+I and C+A (median, 5.70 vs.4.03 months, hazard ratio 0.92, 95% CI: 0.46-1.85, p=0.87), despite of PD-L1 expression or tumor mutational burden.
Conclusions
In the taxanes, nab-paclitaxel might improve survival outcomes than docetaxel for HER2-altered patients. Chemotherapy plus immune checkpoint inhibitors might yield more survival benefits than chemotherapy alone in the second or third-line setting in HER2-altered NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.